濮阳东方医院位置在哪濮阳东方妇科医院看病专业吗,濮阳东方男科医院割包皮收费正规,濮阳东方医院妇科几点上班,濮阳东方男科收费低服务好,濮阳东方医院看早泄技术非常哇塞,濮阳东方医院看妇科技术值得放心,濮阳东方医院看男科病价格公开

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Aug. 24 (Xinhua) -- China will prioritize the development of six types of new materials in its new material industry over the next five years, the China Securities Journal said on Wednesday.The report cited an insider, who noted that the country's 12th Five-Year Plan (2011-2015) for the new material industry will come out in September, in which the government will launch key projects to support the development of the six materials.The six materials will be high-strength light alloy, advanced iron and steel, carbon fiber composite, new power battery material, function coated material, and rare earth function material, according to the report.The plan states each of the six sub industries will form a sizable industrial scale, with the industry's total output value to hit trillions of yuan by the end of 2015, and the self-supply rate to reach 70 percent during the period, the report said.Meanwhile, the government will also foster the development of materials in sectors such as green building material and the biomedical industry over the next five years, it added.

WASHINGTON, Aug. 31 (Xinhua) -- Astronomers using NASA's Chandra X-ray Observatory discovered the first pair of supermassive black holes in a spiral galaxy similar to the Milky Way, NASA announced Wednesday.Approximately 160 million light years from Earth, the pair is the nearest known such phenomenon.The black holes are located near the center of the spiral galaxy NGC 3393. Separated by only 490 light years, the black holes are likely the remnant of a merger of two galaxies of unequal mass a billion or more years ago.Both of the supermassive black holes are heavily obscured by dust and gas, which makes them difficult to observe in optical light. Because X-rays are more energetic, they can penetrate this obscuring material. Chandra's X-ray spectra show clear signatures of a pair of supermassive black holes."If this galaxy weren't so close, we'd have no chance of separating the two black holes the way we have," said Pepi Fabbiano of the Harvard-Smithsonian Center for Astrophysics, who led the study that appeared Wednesday in on-line issue of the journal Nature. "Since this galaxy was right under our noses by cosmic standards, it makes us wonder how many of these black hole pairs we've been missing."Previous observations in X-rays and at other wavelengths indicated that a single supermassive black hole existed in the center of NGC 3393. However, a long look by Chandra allowed the researchers to detect and separate the dual black holes. Both black holes are actively growing and emitting X-rays as gas falls towards them and becomes hotter.When two equal-sized spiral galaxies merge, astronomers think it should result in the formation of a black hole pair and a galaxy with a disrupted appearance and intense star formation. A well-known example is the pair of supermassive black holes in NGC 6240, which is located about 330 million light years from Earth.However, NGC 3393 is a well-organized spiral galaxy, and its central bulge is dominated by old stars. These are unusual properties for a galaxy containing a pair of black holes.

BERLIN, June 1 (Xinhua) -- Germany's disease control center reported on Wednesday 365 new cases of the fatal enterohemorrhagic E. coli (EHEC), which marked a sharp rise since its outbreak in the middle of May.Twenty-five percent of the new cases involved the hemolytic- uremic syndrome (HUS), a serious complication resulting from E. coli infection that affects the blood and kidneys, Germany's Robert Koch Institute said.Until now 17 people in Europe, one in Sweden, the other in Germany have been killed by the deadly disease, while the source of the infection was still not identified.According to the data of Robert Koch Institute, at present 470 patients are suffering from HUS due to the infection, raising concerns that the death toll could be even higher in the future.Germany's Agriculture and Consumer Protection Minister Ilse Aigner defended Germany's previous alert on cucumbers from Spain on Wednesday."The fatal strain of EHEC bacteria was indeed found on Spanish cucumbers. According to the European rules, a quick warning must be sent out," she told a local TV station.Laboratory tests in Hamburg on Tuesday overthrew the previous finding that Spanish cucumbers were the sources of the outbreak.As a result of the alert, Europe and Russia imposed bans on Spanish vegetables, leaving Spanish farmers a loss of 200 million euros (287.5 million U.S. dollars) a week.Spain has expressed its intention to take possible legal actions against authorities in Hamburg and ask for compensations from Germany and the European Union.

SAN FRANCISCO, July 14 (Xinhua) -- Microsoft on Thursday introduces a hacking alert system to its Windows Live Hotmail email service alongside banning common passwords."When someone's account gets hijacked, their friends often find out before they do, because the hijacker uses their account to send spam or phishing email to all their contacts," said Microsoft in a blog post.The new security feature adds a "My friend's been hacked!" option in the "mark as" menu in Hotmail and also enables users to report hacked accounts via the junk mail filing screen.Then an alert will be sent to Microsoft, which will "make sure the account can no longer be used by spammers and activates an account recovery process to allow the owner to take back control the accounts."Users can report any email account as compromised and Hotmail will provide the information to other email providers like Yahoo! and Gmail, said the blog.Meanwhile, Microsoft said Hotmail will roll out a feature to prevent users from choosing commonly used and weak passwords, such as "123456," "ilovecats" and "gogiants." Users who currently use a weak password will be asked to change to a stronger one in the future.Hotmail, first launched in July 1996, is one of the first free email providers, and was acquired by Microsoft in 1997 for an estimated 400 million U.S. dollars.According to statistics released by comScore last August, Hotmail was then the world's largest web-based email service with around 364 million users, followed by Yahoo! Mail (280 million) and Gmail (191 million).